Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

12.63USD
5:18pm BST
Change (% chg)

$-0.35 (-2.70%)
Prev Close
$12.98
Open
$12.55
Day's High
$12.67
Day's Low
$12.30
Volume
175,365
Avg. Vol
737,728
52-wk High
$22.38
52-wk Low
$3.01

Latest Key Developments (Source: Significant Developments)

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT.ARROWHEAD PHARMA- U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO ARO-AAT FOR TREATMENT OF A RARE GENETIC LIVER DISEASE.  Full Article

Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B.  Full Article

Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS.ARROWHEAD PHARMACEUTICALS INC QTRLY LOSS PER SHARE $‍0.18​.SAYS QTRLY REVENUE $3.5 MILLION VERSUS $4.4 MILLION.  Full Article

Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Silence Therapeutics Plc ::‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​.DEAL ‍FOR A TOTAL CONSIDERATION OF $11.3 MILLION​.  Full Article

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT.ARROWHEAD PHARMACEUTICALS INC - APPLICATION FOR APPROVAL OF CLINICAL TRIAL WAS SUBMITTED TO NEW ZEALAND MEDICINES AND MEDICAL DEVICES SAFETY AUTHORITY.  Full Article

Silence Therapeutics Cuts Stake In Arrowhead Pharma To 3.7 Pct From 6.4 Pct
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Arrowhead Pharmaceuticals Inc ::SILENCE THERAPEUTICS PLC CUTS STAKE IN ARROWHEAD PHARMACEUTICALS TO 3.7 PERCENT AS OF DECEMBER 8 FROM A STAKE OF 6.4 PERCENT AS OF NOVEMBER 29 - SEC FILING.  Full Article

Silence Therapeutics Plc Reports 6.4 Pct Stake In Arrowhead Pharmaceuticals As Of Nov 29
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Arrowhead Pharmaceuticals Inc ::SILENCE THERAPEUTICS PLC REPORTS 6.4 PERCENT STAKE IN ARROWHEAD PHARMACEUTICALS INC AS OF NOVEMBER 29 - SEC FILING.SILENCE THERAPEUTICS SAYS ACQUIRED ARROWHEAD PHARMACEUTICALS' COMMON STOCK IN ORDER TO FACILITATE DISCUSSIONS REGARDING POSSIBLE TRANSACTION WITH THEM.  Full Article

Arrowhead Qtrly loss per share $0.07
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Arrowhead Pharmaceuticals Inc ::Arrowhead reports fiscal 2017 third quarter results.Qtrly loss per share $0.07.Qtrly revenue $9.3 million versus $39,583.  Full Article

Arrowhead reports Q2 revenue $9 million
Wednesday, 3 May 2017 

May 3 (Reuters) - Arrowhead Pharmaceuticals Inc :Arrowhead reports fiscal 2017 second quarter results.Qtrly loss per share $0.08.Q2 revenue $9 million versus $43,750.  Full Article

Arrowhead reports qtrly loss per share $0.17
Monday, 6 Feb 2017 

Arrowhead Pharmaceuticals Inc : Arrowhead reports fiscal 2017 first quarter results .Qtrly loss per share (basic and diluted) $0.17.  Full Article

Photo

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.